JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

NVO

67.74

+0.61%↑

UNH

302.46

+0.12%↑

NVS

120.31

+2.04%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

NVO

67.74

+0.61%↑

UNH

302.46

+0.12%↑

NVS

120.31

+2.04%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

NVO

67.74

+0.61%↑

UNH

302.46

+0.12%↑

NVS

120.31

+2.04%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

NVO

67.74

+0.61%↑

UNH

302.46

+0.12%↑

NVS

120.31

+2.04%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

NVO

67.74

+0.61%↑

UNH

302.46

+0.12%↑

NVS

120.31

+2.04%↑

Search

Eli Lilly and Co.

Uždarymo kaina

SektoriusSveikatos priežiūra

795.48 0.43

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

785.34

Max

798.46

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-6.1B

2.8B

Pardavimai

-804M

13B

P/E

Sektoriaus vid.

62.756

50.291

Pelnas, tenkantis vienai akcijai

3.34

Dividendų pajamingumas

0.79

Pelno marža

21.678

Darbuotojai

47,000

EBITDA

-2B

4.2B

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+26.16% upside

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

0.79%

2.40%

Kitas uždarbis

2025-08-06

Kitas dividendų mokėjimo data

2025-09-10

Kita Ex Dividend data

2025-08-15

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-136B

692B

Ankstesnė atidarymo kaina

795.05

Ankstesnė uždarymo kaina

795.48

Naujienos nuotaikos

By Acuity

38%

62%

125 / 380 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

Eli Lilly and Co. Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-06-17 11:56; UTC

Įsigijimai, susijungimai, perėmimai

Eli Lilly to Acquire Verve Therapeutics for Up to $1.3 Billion

2025-05-27 14:41; UTC

Įsigijimai, susijungimai, perėmimai

Eli Lilly to Acquire SiteOne Therapeutics for Up to $1 Billion

2025-06-17 14:02; UTC

Įsigijimai, susijungimai, perėmimai

Eli Lilly's $1.3 Billion Bid Sends Verve Therapeutics Stock Soaring. What to Know. -- Barrons.com

2025-06-17 12:12; UTC

Įsigijimai, susijungimai, perėmimai

Eli Lilly's $1.3 Billion Bid Sends Verve Therapeutics Stock Soaring 77%. What to Know. -- Barrons.com

2025-06-17 11:01; UTC

Įsigijimai, susijungimai, perėmimai

This Stock Just Jumped 77% After Eli Lilly Made an Agreed $1.3 Billion Bid -- Barrons.com

2025-06-17 10:47; UTC

Įsigijimai, susijungimai, perėmimai

Eli Lilly: Total Potential Consideration of Up to $13.50 Per Shr in Cash Without Interest >LLY

2025-06-17 10:47; UTC

Įsigijimai, susijungimai, perėmimai

Eli Lilly: Considering Also Includes One Non-Tradeable Contingent Value Right Per Shr That Entitles Holder to Receive Up to an Additional $3 Per Shr >LLY

2025-06-17 10:46; UTC

Įsigijimai, susijungimai, perėmimai

Eli Lilly Will Commence Tender Offer to Acquire All Outstanding Shrs of Verve for Purchase Price of $10.50 Per Shr in Cash >LLY

2025-06-17 10:45; UTC

Įsigijimai, susijungimai, perėmimai

Lilly To Acquire Verve Therapeutics To Advance One-time Treatments For People With High Cardiovascular Risk >LLY VERV

2025-06-17 09:33; UTC

Įsigijimai, susijungimai, perėmimai

Eli Lilly Close to $1.3 Billion Bid for Biotech, Says Report. Verve Therapeutics Stock Soars 80%. -- Barrons.com

2025-06-11 09:45; UTC

Rinkos pokalbiai

Next Generation Obesity Drugs in Focus at American Diabetes Association Event -- Market Talk

2025-05-29 01:00; UTC

Svarbiausios naujienos

How Ozempic's Maker Lost Its Grip on the Obesity Market It Created -- WSJ

2025-05-28 18:09; UTC

Uždarbis

Heart Disease Could Be a Goner When These New -2-

2025-05-28 18:09; UTC

Uždarbis

Heart Disease Could Be a Goner When These New Drugs Arrive -- Barrons.com

2025-05-27 14:02; UTC

Įsigijimai, susijungimai, perėmimai

Eli Lilly: SiteOne Deal Includes Phase-2-Ready STC-004 for Treatment of Pain >LLY

2025-05-27 14:01; UTC

Įsigijimai, susijungimai, perėmimai

Eli Lilly: SiteOne Deal Includes Upfront, Milestone Payments >LLY

2025-05-27 14:00; UTC

Įsigijimai, susijungimai, perėmimai

Eli Lilly to Buy SiteOne Therapeutics For Up to $1 Billion in Cash >LLY

2025-05-27 14:00; UTC

Įsigijimai, susijungimai, perėmimai

Lilly To Expand Its Pain Pipeline With Acquisition Of SiteOne Therapeutics >LLY

2025-05-20 14:08; UTC

Uždarbis

Novo Nordisk Woes Weigh on Denmark's Economy. Here's How. -- Barrons.com

2025-05-12 22:14; UTC

Svarbiausios naujienos

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- 2nd Update

2025-05-12 18:45; UTC

Svarbiausios naujienos

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- Update

2025-05-12 17:14; UTC

Svarbiausios naujienos

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- WSJ

2025-05-07 17:01; UTC

Svarbiausios naujienos

Teva Will Hike Generic Drug Prices If Trump Imposes Tariffs, CEO Says -- Barrons.com

2025-05-07 13:56; UTC

Uždarbis

Novo Nordisk Stock Jumps After Earnings. Compounding Market's Growth Took it By Surprise -- Barrons.com

2025-05-07 11:18; UTC

Uždarbis

Novo Nordisk Stock Jumps After Earnings. It Cuts Guidance as Weight-Loss Drug Sales Slow. -- Barrons.com

2025-05-07 09:30; UTC

Svarbiausios naujienos

Trump Is Threatening Big Pharma With Tariffs. Tax Changes Might Work Better. -- Heard on the Street -- WSJ

2025-05-06 20:30; UTC

Svarbiausios naujienos

Novo Nordisk Reports Earnings Soon. The Wegovy Manufacturer Is Scrambling to Hold Market Share. -- Barrons.com

2025-05-04 04:05; UTC

Įsigijimai, susijungimai, perėmimai

UnitedHealth's Stock Is Ailing. A Bigger Business Hasn't Helped. -- Barrons.com

2025-05-01 21:07; UTC

Rinkos pokalbiai

Weight-Loss Drug Competitive Pressures Hammer Eli Lilly Shares -- Market Talk

2025-05-01 14:07; UTC

Uždarbis

Eli Lilly Earnings Beat Expectations. Why the Stock Is Falling. -- Barrons.com

Akcijų palyginimas

Kainos pokytis

Eli Lilly and Co. Prognozė

Kainos tikslas

By TipRanks

26.16% į viršų

12 mėnesių prognozė

Vidutinis 999.57 USD  26.16%

Aukščiausias 1,190 USD

Žemiausias 700 USD

Remiantis 19 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Eli Lilly and Co. kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

19 ratings

16

Pirkti

2

Laikyti

1

Parduoti

Techninis įvertinimas

By Trading Central

N/A / 884.54Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Very Strong Bearish Evidence

Vidutinės trukmės periodas

Bullish Evidence

Ilgalaikis periodas

Strong Bearish Evidence

Rinkos nuotaikos

By Acuity

125 / 380 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Aukščiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Eli Lilly and Co.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It operates Lilly Seaport Innovation Center (LSC), a research and development facility in the Boston Seaport to advancing Lilly's efforts in RNA and DNA-based therapies as well as discovering new drug targets to create life-changing medicines across several disease states, including diabetes, obesity, cardiovascular diseases, neurodegeneration, and chronic pain. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; and Chugai Pharmaceutical Co., Ltd, as well as development collaboration with Eli Lilly and Company for developing QIAstat-Dx IVD panel, for the detection of various APOE genotypes. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.